tiprankstipranks
Advertisement
Advertisement

NUVL Stock Latest News

De-Risked Oncology Pipeline and Strong Cash Position Underpin Outperform Rating and $125 Target
RatingsDe-Risked Oncology Pipeline and Strong Cash Position Underpin Outperform Rating and $125 Target
23d ago
NUVL
Nuvalent price target raised to $138 from $132 at UBS
PremiumThe Fly
Nuvalent price target raised to $138 from $132 at UBS
23d ago
NUVL
Nuvalent: Buy Rating Backed by Late‑Stage Oncology Pipeline and Upcoming Value‑Driving Milestones
PremiumRatings
Nuvalent: Buy Rating Backed by Late‑Stage Oncology Pipeline and Upcoming Value‑Driving Milestones
23d ago
NUVL
Nuvalent price target raised to $140 from $135 at Cantor Fitzgerald
PremiumThe Fly
Nuvalent price target raised to $140 from $135 at Cantor Fitzgerald
26d ago
NUVL
Nuvalent reports Q4 EPS ($1.58), consensus ($1.44)
PremiumThe Fly
Nuvalent reports Q4 EPS ($1.58), consensus ($1.44)
27d ago
NUVL
Nuvalent files automatic mixed securities shelf
PremiumThe FlyNuvalent files automatic mixed securities shelf
3M ago
NUVL
Nuvalent price target lowered to $145 from $147 at JPMorgan
Premium
The Fly
Nuvalent price target lowered to $145 from $147 at JPMorgan
3M ago
NUVL
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
3M ago
FHTX
NUVL
Nuvalent’s Royalty Interest Acquired by Royalty Pharma
PremiumCompany Announcements
Nuvalent’s Royalty Interest Acquired by Royalty Pharma
3M ago
8K
NUVL
Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
PremiumThe Fly
Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
3M ago
NUVL
RPRX
Ron Squarer Joins Nuvalent Board as Independent Director
PremiumCompany Announcements
Ron Squarer Joins Nuvalent Board as Independent Director
3M ago
8K
NUVL
Nuvalent initiated with a Buy at Truist
PremiumThe Fly
Nuvalent initiated with a Buy at Truist
4M ago
NUVL
Nuvalent Announces $500M Stock Offering Pricing
PremiumCompany AnnouncementsNuvalent Announces $500M Stock Offering Pricing
4M ago
8K
NUVL
Nuvalent’s New Drug Application for zidesamtinib in NSCLC acepted by FDA
Premium
The Fly
Nuvalent’s New Drug Application for zidesamtinib in NSCLC acepted by FDA
4M ago
NUVL
Nuvalent 4.95M share Secondary priced at $101.00
Premium
The Fly
Nuvalent 4.95M share Secondary priced at $101.00
4M ago
NUVL
Nuvalent price target raised to $135 from $120 at Goldman Sachs
PremiumThe Fly
Nuvalent price target raised to $135 from $120 at Goldman Sachs
4M ago
NUVL
Nuvalent price target raised to $155 from $125 at Guggenheim
PremiumThe Fly
Nuvalent price target raised to $155 from $125 at Guggenheim
4M ago
NUVL
Nuvalent price target raised to $158 from $112 at Baird
PremiumThe Fly
Nuvalent price target raised to $158 from $112 at Baird
4M ago
NUVL
Nuvalent’s Neladalkib Shows Superior Efficacy and Safety in Clinical Trials
PremiumRatings
Nuvalent’s Neladalkib Shows Superior Efficacy and Safety in Clinical Trials
4M ago
NUVL
Nuvalent announces $500M Class A common stock offering
PremiumThe FlyNuvalent announces $500M Class A common stock offering
4M ago
NUVL
Nuvalent price target raised to $152 from $112 at Barclays
Premium
The Fly
Nuvalent price target raised to $152 from $112 at Barclays
4M ago
NUVL
Nuvalent rises 15.8%
Premium
The Fly
Nuvalent rises 15.8%
4M ago
NUVL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >